Aclarubicin disrupts RNA polymerase II progression at replication-coupled histone genes
This study reveals that aclarubicin selectively disrupts RNA polymerase II progression at replication-coupled histone genes due to their dense transcriptional activity, causing nonproductive polymerase accumulation and establishing these loci as key targets for the drug's chromatin-based anticancer mechanism.